Digitalis Ventures

Digitalis is a venture capital firm founded in 2016 and headquartered in New York, New York, with additional offices in Boston, Los Angeles, and San Francisco. It focuses on investing in innovative solutions addressing complex challenges in human and animal health. Digitalis collaborates with entrepreneurs, inventors, and scientists at various stages of development, targeting companies within the healthcare, life sciences, and animal health sectors. The firm aims to support advancements in these fields by providing the necessary financial resources and expertise to foster growth and innovation.

Steve Allen

Partner

Cindy Cole

Technical Partner

Auro Nair

Partner

Dac Nguyen

Technical Partner

Victoria Perweiler

Venture Partner

Drew Taylor

Partner

Misti Ushio

Managing Partner

Past deals in Pets

PetMedix

Series B in 2021
PetMedix Ltd is a veterinary biopharmaceutical company based in Cambridge, UK, focused on developing therapeutic drug discovery tools and platforms for pets. Founded in 2017, the company specializes in creating transgenic mouse platforms, such as Ky9 and Felyne, which produce therapeutic-quality antibody drugs specifically tailored for companion animals. Leveraging over thirty years of expertise in human drug development, PetMedix aims to generate a diverse repertoire of monoclonal antibodies that aligns with the immune systems of pets. This innovation enables veterinary professionals to provide effective and safe treatments, ultimately contributing to the health and well-being of animals.

AnimalBiome

Venture Round in 2021
AnimalBiome focuses on improving the gut health of dogs and cats in the United States that suffer from chronic digestive disorders. The company offers microbiome-based supplements and non-invasive diagnostic tools designed to identify imbalances in the gut microbiome. Utilizing deoxyribonucleic acid sequencing, AnimalBiome's diagnostic services assess the balance of gut bacteria, allowing pet owners to gain insights into their pets' gut health. This information enables tailored supplementation aimed at restoring gut balance, ultimately promoting a healthier and happier life for pets.

Rejuvenate Bio

Series A in 2021
Rejuvenate Bio Inc is a biotechnology company based in Brookline, Massachusetts, founded in 2017. The company specializes in developing gene therapies aimed at enhancing the health and longevity of domesticated animals, particularly dogs. Rejuvenate Bio offers anti-aging treatments by introducing new DNA instructions into the animals' bodies. Additionally, the company provides gene therapies designed to target and cure specific diseases in pets, contributing to improved overall well-being and lifespan.

Smalls

Series A in 2020
Smalls is a direct-to-consumer pet food company based in New York that specializes in producing fresh, human-grade food for cats. Founded in 2017 by Matt Michaelson and Calvin, the company offers a range of cat food options, including chicken, beef, turkey, and duck, which are prepared with fresh meat and a small amount of green vegetables. The food is gently cooked to preserve nutrients and moisture, ensuring high quality. Smalls provides customized meal kits tailored to the specific nutritional needs of each cat, allowing pet owners to conveniently receive healthy and fresh food delivered directly to their homes.

Scratch

Series B in 2019
Scratch Financial, operating under the brand Scratchpay, is the leading provider of accessible payment plans for veterinary care in the United States. Established in 2016 by Caleb Morse and John Keatley, the company is based in Los Angeles, California. Scratchpay collaborates with veterinary clinics to offer pet owners straightforward and pet-friendly financing options. The platform allows users to apply for and receive approval for payment plans in approximately 90 seconds, facilitating timely access to essential veterinary services. Scratchpay aims to enhance the affordability and transparency of veterinary care, ultimately ensuring that more pet owners can obtain the medical attention their animals require.

Pawp

Seed Round in 2019
Pawp, Inc. is a pet care service provider that offers an online platform designed to assist pet owners in managing their pets' health and accessing veterinary care. Founded in 2018 and based in New York, the company provides users with unlimited 24/7 access to licensed veterinarians, significantly reducing the need for unnecessary vet visits. Pawp also offers a pet emergency fund of $3,000 per year, which serves as a financial safety net for unexpected veterinary expenses. By combining veterinary access with emergency funding, Pawp aims to make pet care more affordable and accessible, allowing pet owners to make informed health decisions for their animals.

PetMedix

Series A in 2019
PetMedix Ltd is a veterinary biopharmaceutical company based in Cambridge, UK, focused on developing therapeutic drug discovery tools and platforms for pets. Founded in 2017, the company specializes in creating transgenic mouse platforms, such as Ky9 and Felyne, which produce therapeutic-quality antibody drugs specifically tailored for companion animals. Leveraging over thirty years of expertise in human drug development, PetMedix aims to generate a diverse repertoire of monoclonal antibodies that aligns with the immune systems of pets. This innovation enables veterinary professionals to provide effective and safe treatments, ultimately contributing to the health and well-being of animals.

MollyBox

Series B in 2018
MollyBox is a subscription-based e-commerce platform for pet-owners. The company offers a monthly themed box of pet foods and supplies. MollyBox was founded in 2015 by Yifu Sun and Yi Ju and is based in Shanghai, China.

Rejuvenate Bio

Seed Round in 2018
Rejuvenate Bio Inc is a biotechnology company based in Brookline, Massachusetts, founded in 2017. The company specializes in developing gene therapies aimed at enhancing the health and longevity of domesticated animals, particularly dogs. Rejuvenate Bio offers anti-aging treatments by introducing new DNA instructions into the animals' bodies. Additionally, the company provides gene therapies designed to target and cure specific diseases in pets, contributing to improved overall well-being and lifespan.

Scratch

Series A in 2018
Scratch Financial, operating under the brand Scratchpay, is the leading provider of accessible payment plans for veterinary care in the United States. Established in 2016 by Caleb Morse and John Keatley, the company is based in Los Angeles, California. Scratchpay collaborates with veterinary clinics to offer pet owners straightforward and pet-friendly financing options. The platform allows users to apply for and receive approval for payment plans in approximately 90 seconds, facilitating timely access to essential veterinary services. Scratchpay aims to enhance the affordability and transparency of veterinary care, ultimately ensuring that more pet owners can obtain the medical attention their animals require.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.